Polycystic Kidney, Autosomal Dominant
Pipeline by Development Stage
Drug Modality Breakdown
Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.
Key Trends
- GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
- Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
- Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research
Career Verdict
Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 25% | Peak | Stable | 12.4yr |
| 2 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 24% | Peak | Stable | 8.6yr |
| 3 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 20% | Peak | Stable | |
| 4 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 12% | Peak | Stable | 15.4yr |
Drug Class Breakdown
cardiometabolic dominance
cardioprotective expansion
heart failure crossover
overactive bladder niche
declining relevance
Career Outlook
StableNephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.
Breaking In
Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.
For Experienced Professionals
Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.
In-Demand Skills
Best For
Hiring Landscape
Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.
Top Hiring Companies
By Department
Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.
On Market (3)
Approved therapies currently available
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (12)
Total enrollment: 4,276 patients across 12 trials
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Octreotide in Severe Polycystic Liver Disease
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
Feasibility Study of Metformin Therapy in ADPKD
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
Related Jobs in Nephrology
Project Manager, On-Market Products - Pleasanton, CA
Staff Systems Engineer - Pleasanton, CA
Area Sales Manager (Georgia)
Farm Operations Technician
Sr. Research and Development Technician - Pleasanton, CA
Chicago South based Clinical Specialist - Remote, USA
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.